Publications by authors named "Dong-Wan Choi"
Article Synopsis
- This study investigates the efficacy, safety, and pharmacokinetics of an 80 mg daily dose of osimertinib in patients with leptomeningeal metastases (LMs) who have previously been treated with other EGFR tyrosine kinase inhibitors (TKIs).
- A total of 73 patients were treated, and findings include a median overall survival of 15.6 months and a 51.6% objective response rate, indicating substantial effectiveness in controlling the disease.
- The results support the use of osimertinib as a promising treatment option for patients with EGFR-mutated non-small cell lung cancer who develop LMs, highlighting its significant intracranial activity and manageable safety profile.
Article Synopsis
- The study analyzed the effectiveness and safety of lazertinib compared to gefitinib in treating Korean patients with EGFR-mutated non-small cell lung cancer (NSCLC) as part of the phase 3 LASER301 trial.
- A total of 172 patients were randomized to receive either lazertinib (240 mg/day) or gefitinib (250 mg/day), with the main goal of assessing progression-free survival (PFS).
- Results showed that lazertinib significantly improved median PFS (20.8 months) compared to gefitinib (9.6 months) and had a similar safety profile, suggesting lazertinib could be a promising new treatment option for these patients.
In a previous study, we developed a new analgesic index using nasal photoplethysmography (nasal photoplethysmographic index, NPI) and showed that the NPI was superior to the surgical pleth index (SPI) in distinguishing pain above numerical rating scale 3. Because the NPI was developed using data obtained from conscious patients with pain, we evaluated the performance of NPI in comparison with the SPI and the analgesia nociception index (ANI) in patients under general anaesthesia with target-controlled infusion of propofol and remifentanil. The time of nociception occurrence was defined as when the signs of inadequate anaesthesia occurred.
View Article and Find Full Text PDFPurpose: To determine the efficacy of consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents in locally advanced non-small-cell lung cancer (LA-NSCLC).
Patient And Methods: Patients were randomly assigned to either CCRT alone (observation arm) or CCRT followed by CC (consolidation arm). CCRT with docetaxel (20 mg/m(2)) and cisplatin (20 mg/m(2)) was administered every week for 6 weeks with a total dose of 66 Gy of thoracic radiotherapy in 33 fractions.
Aim: To evaluate the success rates, procedural time and adverse event rates of the modified methods in endoscopic ultrasonography-guided hepaticogastrostomy (EUS-HGS).
Methods: Twenty-eight patients in a prospective case series who underwent EUS-HGS (phase I). Forty-six patients in a matched case-control study (phase II).